Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial
Prithviraj Bose, Haris Ali, Haifa Kathrin Al-Ali, Valentín García‐Gutiérrez et autres
PURPOSE Ruxolitinib improves splenomegaly and symptoms in myelofibrosis (MF) but lacks reliable clonal burden reduction. Selinexor, an oral inhibitor of exportin 1, has demonstrated activity in MF. We evaluated selinexor plus ruxolitinib versus ruxolitinib alone in Janus kinase inhibitor–naïve MF. METHODS In …
us, de, es, pl, bg, gb, kr, tw, fr, it, ro (code pays fourni par la source)
2 citations
Journal of Clinical Oncology